6月25日，Ascendis Pharma盘中上涨8.3%，报259.16美元/股，成交额3.27亿美元。
消息面上，公司近期公布了核心产品Yorvipath（TransCon PTH）治疗甲状旁腺功能减退症的多项长期数据，市场持续消化利好。三期PaTHway研究3.5年数据显示综合应答率达86%，89%患者完成试验；二期PaTH Forward研究5年数据显示应答率82%，肾功能持续改善。Wedbush发布研报称Yorvipath相较竞品保持显著优势，维持跑赢大市评级及273美元目标价。此外，竞争对手MBX Biosciences同适应症药物二期应答率仅57%，进一步凸显Yorvipath的领先地位。目前华尔街分析师对该股平均目标价约284美元，巴克莱给出342美元最高目标价。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.